Please Wait a Moment
X

Articles

23Jul

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

23 Jul, 2020 | Return|

After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.

Read all about it on the Communication page by clicking this link: Communications

Related

VP, Scientific Affairs Dr. Marion Lanteri Speaks at Symposium on Alternatives to Donation Deferral

As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...

Read More >

COVID-19 Antibody Testing Frequently Asked Questions

The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...

Read More >

Upcoming HCV Testing Algorithm Change

FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...

Read More >

Special Testing Laboratory Test Result Reporting Change

An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...

Read More >

Convalescent Plasma Testing for COVID-19

CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...

Read More >

CTS Tampa Implements New Laboratory Information System

On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...

Read More >